MiNK Therapeutics (INKT) Stock Surges 80% on C-Further Pediatric Cancer Deal

TLDR

• MiNK Therapeutics (INKT) stock jumped 80% Tuesday after announcing a collaboration with C-Further.
• The deal targets PRAME, a tumor-associated antigen found in several pediatric cancers including sarcomas and leukemia.
• MiNK will receive ~$1.1 million in non-dilutive funding tied to scientific milestones.
• The agreement includes a double-digit share of potential downstream commercial revenues.
• The collaboration is non-exclusive, so MiNK can continue pursuing other oncology deals independently.

MiNK Therapeutics stock shot up 80% on Tuesday after the company announced a new collaboration with C-Further, a pediatric oncology therapeutics consortium.

MiNK Therapeutics, Inc., INKT

The deal centers on developing a PRAME-targeted iNKT cell therapy for children with cancer. PRAME is a tumor-associated antigen found across several pediatric malignancies.

Under the agreement, MiNK will receive approximately $1.1 million in non-dilutive funding. That means the company doesn’t have to give up equity to access the cash.

Payments are tied to hitting defined scientific milestones, covering preclinical candidate nomination and translational development stages. There’s also a double-digit revenue share on potential future commercial sales.

MiNK’s iNKT platform is built as an off-the-shelf therapy. It’s derived from healthy donors, manufactured in advance, and can be delivered without HLA matching or lymphodepleting chemotherapy — a key practical advantage.

The program targets PRAME, which is highly expressed in multiple pediatric malignancies including sarcomas, acute myeloid leukemia, and medulloblastoma. PRAME shows limited expression in healthy tissue, making it an attractive therapeutic target.

C-Further is enabled by Cancer Research Horizons, LifeArc, and Great Ormond Street Hospital Charity. Its focus is on accelerating immunotherapies for children with cancers that have few treatment options.

MiNK will serve as the lead industry partner on the project. The company brings its iNKT platform, engineering capabilities, and translational development expertise to the collaboration.

Preclinical Work and University Partnership

Investigators at the University of Southampton will run independent preclinical studies. These will evaluate anti-tumor activity, persistence, and safety across multiple pediatric cancer models, including patient-derived tumor systems.

The goal is to nominate a single lead clinical candidate. That candidate would then move toward first-in-human studies in children.

This program is one of the first selected by the C-Further consortium since it launched. That timing makes MiNK one of the earliest companies to be brought into the initiative.

Non-Exclusive Deal Keeps Options Open

The agreement is non-exclusive. MiNK retains the freedom to continue developing its iNKT platform across other oncology indications and additional partnerships.

That structure matters for investors. It means the C-Further deal doesn’t lock MiNK into a single path — the company can keep building out its broader pipeline in parallel.

MiNK’s iNKT platform works by combining PRAME-specific antigen recognition with the unique biology of iNKT cells, which bridge innate and adaptive immunity.

The program aims to enable precise tumor targeting while also triggering coordinated immune responses within the tumor microenvironment.

INKT stock closed up 80% on Tuesday. The stock had been trading at low levels prior to the announcement, so the move reflects a sharp reaction to the news.

The post MiNK Therapeutics (INKT) Stock Surges 80% on C-Further Pediatric Cancer Deal appeared first on CoinCentral.